Printer Friendly

New members of the board of editors.

We welcome the new members of the Editorial Board whose terms began January 1, 2006.

Patrick M. Bossuyt, PhD, is professor of Clinical Epidemiology at the University of Amsterdam and heads the Department of Clinical Epidemiology and Biostatistics of the Academic Medical Center in Amsterdam. He originally trained in psychology at the University of Ghent (Belgium), with an emphasis on research methodology and judgment and decision behavior, and received a PhD in 1990 from the University of Nijmegen (The Netherlands). Before his present appointment, Dr. Bossuyt worked at the Center for Clinical Decision Making of the Erasmus University in Rotterdam, supporting clinical research projects in what is now Erasmus Medical Center.

[ILLUSTRATION OMITTED]

In 1991, Dr. Bossuyt moved to the Department of Clinical Epidemiology and Biostatistics of the Academic Medical Center of the University of Amsterdam. His scientific work mirrors that of the department, covering a broad range of topics and developed in close collaboration with clinical departments, with an emphasis on research on the effectiveness of clinical interventions and medical technology assessment.

Dr. Bossuyt shares with several other members of the department a special interest in evaluating medical tests. He spearheaded the STARD initiative for the improved reporting of diagnostic test accuracy studies. Dr. Bossuyt has authored or coauthored more than 300 publications in peer-reviewed journals and serves on the editorial boards of several of these. He is a member of the Dutch Health Council.

Kevin Coombes received his PhD in pure mathematics in 1982 from the University of Chicago. He worked in the abstruse areas of algebraic K-theory and arithmetic algebraic geometry during a postdoctoral fellowship at the Massachusetts Institute of Technology, assistant professorships at the University of Oklahoma and the University of Michigan, and an associate professorship at the University of Maryland in College Park. In the mid-1990s, he began to shift his research interests to bioinformatics. Since 2001, he has published more than 35 papers in this area.

Since 1999, Dr. Coombes has been an associate professor in the Department of Biostatistics and Applied Mathematics at the University of Texas M.D. Anderson Cancer Center, where he now heads the Section of Bioinformatics. His current research focuses on statistical, mathematical, and computational methods to understand highly multivariate biological data arising from microarrays, SAGE (serial analysis of gene expression), proteomics, or array CGH (comparative genomic hybridization). He is particularly interested in methods that incorporate existing biological knowledge early in the analytical process.

[ILLUSTRATION OMITTED]

Dr. Coombes has received awards for "Best Presentation" at the 2001 CAMDA (Critical Assessment of Microarray Data Analysis) conference at Duke University for his work on "Biology-driven clustering of microarray data", for "Best Abstract" at the First Annual Proteomics Data Mining Conference for his work on "A comprehensive approach to the analysis of MALDI-TOF proteomics spectra from serum samples", and for "Best Presentation" at the 2002 CAMDA conference for his work on "Organ-specific differences in gene expression and UniGene annotations describing source material".

Marilyn A. Huestis, PhD, is Chief of the Chemistry and Drug Metabolism Section, Intramural Research Program, National Institute on Drug Abuse, NIH, Baltimore, MD. Dr. Huestis received her bachelor's degree in biochemistry from Mount Holyoke, a master's degree in clinical chemistry from the University of New Mexico, and a doctoral degree in toxicology from the University of Maryland, Baltimore.

Dr. Huestis has worked in the fields of forensic and analytical toxicology and clinical chemistry for more than 30 years. Before coming to NIH to conduct controlled clinical drug administration studies, she held positions in clinical and emergency toxicology, therapeutic drug monitoring, urine drug testing, and forensic and analytical toxicology. She is the author of more than 100 papers on pharmacodynamics, pharmacokinetics, and gas chromatography-mass spectrometry, liquid chromatography-mass spectrometry, and tandem mass spectrometry analytical methods for drugs of abuse and licit pharmacotherapies in plasma, urine, oral fluid, sweat, hair, meconium, breast milk, and other alternative matrices.

[ILLUSTRATION OMITTED]

Dr. Huestis' research has focused on the mechanisms of action of cannabinoid agonists and antagonists, documenting for the first time in humans that marijuana's effects in humans are mediated by the CB-1 cannabinoid receptor and can be blocked by the CB-1 cannabinoid receptor antagonist, rimonabant. Her other major research area is fetal exposure to drugs of abuse and methadone and buprenorphine. Pregnant opiate addicts receiving opioid replacement therapy as part of their treatment have provided a unique opportunity to study the disposition of drugs in the mother and fetus and the relationship between drug concentrations and maternal and neonatal outcome measures.

Dr. Huestis is an adjunct associate professor in the Toxicology Program of the University of Maryland, Baltimore, and has the opportunity to mentor toxicology doctoral students. Dr. Huestis has been a member of AACC since 1980 and has served on a variety of AACC committees. She has served as President of the Society of Forensic Toxicology, Chair of the Toxicology Section of the American Academy of Forensic Sciences, and President of The International Association of Forensic Toxicologists. She is on the research advisory board for the United States Anti-Doping Agency and also serves on the editorial boards of the Journal of Analytical Toxicology and Forensic Science International.

W. Greg Miller, PhD, has been on the faculty at Virginia Commonwealth University since 1977. He is currently a professor of pathology and serves the Medical Center as Co-Director of Clinical Chemistry and Director of Pathology Information Systems. He received a PhD in biochemistry from the University of Arizona in 1973, did postdoctoral training in clinical chemistry at the Ohio State University from 1973 to 1975, and became a Diplomat of the American Board of Clinical Chemistry in 1976.

[ILLUSTRATION OMITTED]

Dr. Miller's research interests include interlaboratory standardization, quality control and proficiency testing, reference systems and traceability, analytical measurement systems, and automated information management. He is currently an active contributor to clinical laboratory practice and standardization activities of the College of American Pathologists, Clinical and Laboratory Standards Institute, National Kidney Disease Education Program, American Diabetes Association, National Glycohemoglobin Standardization Program, and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).

Chad A. Mirkin, PhD, is the Director of the Institute for Nanotechnology, the George B. Rathmann Professor of Chemistry, professor of medicine, and professor of materials science at Northwestern University.

Professor Mirkin is a chemist and nanoscience expert who is known for his development of nanoparticle-based biodetection schemes, invention of Dip-Pen nanolithography, and contributions to supramolecular chemistry. He is the author of more than 250 papers and more than 50 patents. He is the founder of two companies, Nanosphere and NanoInk, which are commercializing nanotechnology applications in the life science and semiconductor industries.

Professor Mirkin has been recognized for his accomplishments with an NIH Director's Pioneer Award, the Collegiate Inventors Award, National Inventors Hall of Fame (2002 and 2004), an Honorary Doctorate Degree from Dickinson College, the Pennsylvania State University Outstanding Science Alumni Award, the ACS Nobel Laureate Signature Award for Graduate Education in Chemistry, a Dickinson College Metzger-Conway Fellowship, the 2003 Raymond and Beverly Sackler Prize in the Physical Sciences, the Feynman Prize in Nanotechnology, the Leo Hendrick Baekeland Award, Crain s Chicago Business "40 under 40 Award", the Discover 2000 Award for Technological Innovation, I-Street Magazine's Top 5 List for Leading Academics in Technology, the Materials Research Society Young Investigator Award, the American Chemical Society Award in Pure Chemistry, the PLU Fresenius Award, the Harvard University E. Bright Wilson Prize, the BF Goodrich Collegiate Inventors Award, the Camille Dreyfus Teacher-Scholar Award, the Alfred P. Sloan Foundation Award, the DuPont Young Professor Award, the National Science Foundation Young Investigator Award, the Naval Young Investigator Award, the Beckman Young Investigator Award, and the Camille and Henry Dreyfus Foundation New Faculty Award.

[ILLUSTRATION OMITTED]

He is a Fellow of the American Association for the Advancement of Science and serves on the editorial advisory boards of Accounts of Chemical Research, Advanced Materials, Macromolecular Bioscience, SENSORS, Encyclopedia of Nanoscience and Nanotechnology, Chemistry--A European Journal, Chemistry & Biology, Nanotechnology Law & Business, Journal of Materials Chemistry, Nanotech Briefs, Chemistry World, Plasmonics, The Scientist, Journal of Scanning Probe Microscopy (JSPM), Nanomedicine, Angewandte Chemie, Clinical Chemistry, and the Journal of Cluster Science. Dr. Mirkin is the founding editor of the journal Small.

Dr. Mirkin holds a BS degree from Dickinson College (1986) and a PhD degree in chemistry from the Pennsylvania State University (1989). He was an NSF Postdoctoral Fellow at the Massachusetts Institute of Technology before becoming a chemistry professor at Northwestern University in 1991.

Linda M. Thienpont, Pharm, PhD, is the Director of the Laboratory for Analytical Chemistry, Faculty of Pharmaceutical Sciences, Ghent University, Belgium. She received her Pharmacy degree (1976) and her PhD (1981) from Ghent University. In 1986, after successfully completing her advanced studies and training, she became certified in clinical chemistry and in the use of radioisotopes for in vitro diagnostic tests. In 1989, she earned qualification as a postdoctoral lecturer in bioanalysis (habilitation) and was appointed a full professor in instrumental analytical chemistry at Ghent University, where she also teaches statistics and quality control (advanced studies in clinical biology) and development and validation of analytical methods (master of applied pharmaceutical sciences).

[ILLUSTRATION OMITTED]

Dr. Thienpont's main research interests focus on the development/ validation of Systeme International d'Unites--traceable reference measurement procedures based on isotope-dilution mass spectrometry for analysis of serum metabolites/substrates, total and free steroids/thyroid hormones, peptides, and small proteins. In this field, she works closely with the international diagnostics industry, including the European Commission, Beltest, the European Competent Authorities, the IFCC, proficiency testing providers, and metrology institutes. She is the author of more than 100 publications, mostly in the field of reference measurement procedures but also of graphical and statistical techniques for interpretation of method comparison studies.

As an active participant in several international standardization programs of the Clinical and Laboratory Standards Institute, Dr. Thienpont has chaired the Subcommittee on Free Thyroid Hormone Measurements and currently serves as a member of the Area Committee on Clinical Chemistry and Toxicology. In the IFCC, she has chaired the Working Group on Standardization of Cortisol Measurements and is currently a member of the Committee on Traceability in Laboratory Medicine and chairs the Working Group on Standardization of Thyroid Function Tests. In the Joint Committee on Traceability in Laboratory Medicine, she is cochair of the Working Group on Reference Measurement Laboratories and Networks; in the European Committee for Standardization's Technical Committee 140, in vitro diagnostic systems, she serves as representative for Belgium; and as a member of the European Working Group on Analytical Quality in Laboratory Medicine, she is a contributor to several educational courses.

Per Magne Ueland, MD, PhD, is a professor at the Institute of Internal Medicine, Section of Pharmacology, University of Bergen, Norway, and a Consultant in Clinical Pharmacology at the Haukeland University Hospital in Bergen. He currently heads the Locus for Homocysteine and Related Vitamin research group (http: //www.uib.no/people/mfapu/Pages /LOCUS.html) at the University of Bergen. Dr. Ueland has MD (1973) and PhD (1979) degrees from the University of Bergen and is certified in clinical pharmacology (1989).

Dr. Ueland is an author/coauthor of 300 scientific articles and book chapters, spanning fields from protein characterization, cell biology, analytical chemistry, and instrumentation to clinical and epidemiologic studies. His current research interests focus on the B vitamins (folate, cobalamin, vitamin B6, and riboflavin) and include analytical methods and markers of B-vitamin status and epidemiologic studies of deficiencies of these vitamins as risk factors of chronic diseases, including cardiovascular disease and cancer. Dr. Ueland, along with his research team, has been a coordinator/partner in 3 multicenter projects funded by the European Union. Dr. Ueland received the research award from Falch's Foundation for Medical Science (1990), King Olav the V's Reward for Cancer Research (1992), and a research reward from the Western Regional Health Authority (2003). In 2005, he was recognized by the Norwegian Research Council as the most cited scientist in Norway during the decade 1994-2004.

[ILLUSTRATION OMITTED]

New Scholarship Fund

AACC's Van Slyke Foundation has received a $500 000 contribution from Gopal V. Savjani to create a scholarship fund tentatively entitled the "AACC Past-President's Special Scholarship". Dr. John E. Sherwin, 2006 AACC President, says, "Mr. Copal Savjani's generous donation of $500 000 to the Van Slyke Foundation for the purposes of establishing an 'AACC Past-President's Special Scholarship' in honor of my year as President of AACC overwhelms me. It is my commitment to see that his generous gift is used wisely and that it will recognize our shared commitment to education as well as celebrate our long-standing friendship." For further information, see www. aacc.org.

DOI: 10.1373/clinchem.2006.067678

Compiled by David E. Bruns, Editor (dbruns9clinchem.aacc.org)
COPYRIGHT 2006 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:The Clinical Chemist
Author:Bruns, David E.
Publication:Clinical Chemistry
Date:Mar 1, 2006
Words:2110
Previous Article:Reference Intervals: A User's Guide.
Next Article:Pitfalls in the measurement of circulating vascular endothelial growth factor.
Topics:


Related Articles
AACC Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research, sponsored by Olympus America Inc. Diagnostic Systems...
Dr. Joseph A. Knight receives Pathology Award for Distinguished Service.
AACC's past president's award.
New members of the Board of Editors.
New members of the Board of Editors.
The AACC lectureship award.
AACC Award for Outstanding Contributions to Clinical Chemistry in a selected area of research.
AACC's past-president's award, sponsored by Allegiance Healthcare Corporation, a Cardinal Health Company. (The Clinical Chemist).
New editorial board members.
Martin I. Rubin (1916-2006).

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |